Cite
OA03 Are there any differences in the outcomes of treatment of a 12-month course of rituximab BCD020 biosimilar in systemic lupus erythematosus in children with early and late administration of the drug.
MLA
Kalashnikova, Elvira, et al. “OA03 Are There Any Differences in the Outcomes of Treatment of a 12-Month Course of Rituximab BCD020 Biosimilar in Systemic Lupus Erythematosus in Children with Early and Late Administration of the Drug.” Rheumatology, vol. 62, Aug. 2023, p. 1. EBSCOhost, https://doi.org/10.1093/rheumatology/kead323.003.
APA
Kalashnikova, E., Rinat, R., Lubimova, N., Ekaterina, K., Isupova, E., Gaidar, E., Masalova, V., Snegireva, L., Kornishina, T., Sorokina, L., Kaneva, M., Kalashnikova, O., Burtseva, T., Argunova, V., Sleptsova, P., Chasnyk, V., & Kostik, M. (2023). OA03 Are there any differences in the outcomes of treatment of a 12-month course of rituximab BCD020 biosimilar in systemic lupus erythematosus in children with early and late administration of the drug. Rheumatology, 62, 1. https://doi.org/10.1093/rheumatology/kead323.003
Chicago
Kalashnikova, Elvira, Raupov Rinat, Natalia Lubimova, Kuchinskaya Ekaterina, Eugeniya Isupova, Ekaterina Gaidar, Vera Masalova, et al. 2023. “OA03 Are There Any Differences in the Outcomes of Treatment of a 12-Month Course of Rituximab BCD020 Biosimilar in Systemic Lupus Erythematosus in Children with Early and Late Administration of the Drug.” Rheumatology 62 (August): 1. doi:10.1093/rheumatology/kead323.003.